PTH replacement therapy is not currently used as standard clinical practice according to the European guidelines.(4) However, although the conventional therapies are generally able to control hypocalcaemia, they leave several clinical issues unaddressed: hyperphosphatemia, hypercalciuria, and nephrocalcinosis are a significant burden for many patients, for whom PTH treatment might well be a better alternative. This evidence concerns the gene PTH and nephrocalcinosis.